Trials / NCT06445322
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Recruiting now Observational Natural history / observational
- Sponsor
- Ascidian Therapeutics, Inc
- Treatment
- Prescreening Assessments
- Gene
- Not stated
- Conditions
- Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
- Ages
- 5 Years to no upper limit
- Enrollment
- 50 participants
- Started
- 2024-06-20
- Main results expected
- 2027-08-31
- Results posted
- Not yet
- Record last updated
- 2026-10-09
What the study is testing
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Where it runs
United States (9)
- University of San Francisco, San Francisco, California (terminated)
- Vitreo Retinal Associates, Gainesville, Florida (recruiting now)
- Wilmer Eye Institute at John Hopkins, Baltimore, Maryland (terminated)
- Massachusetts Eye and Ear, Boston, Massachusetts (recruiting now)
- Boston Children's Hospital, Boston, Massachusetts (recruiting now)
- University of Michigan Kellogg Eye Center, Ann Arbor, Michigan (recruiting now)
- Cincinnati Eye Institute, Cincinnati, Ohio (recruiting now)
- Retina Foundation of Texas, Dallas, Texas (recruiting now)
- Retina Consultants of Texas, Houston, Texas (recruiting now)